

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LIEPMANN HOLGER A</u> (Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u> (Street) <u>ABBOTT PARK IL 60064-6400</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/15/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES [ABT]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><u>Senior Vice President</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>03/22/2004</u>
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	61,412	D	
Common shares without par value	12,633 ⁽¹⁾	I	profit sharing trust
Common shares without par value	295 ⁽²⁾	I	by wife for daughter
Common shares without par value	296 ⁽²⁾	I	by wife for daughter

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy) ⁽³⁾	02/13/2001	02/12/2008	Common shares	2,702	37	D	
Option (right to buy) ⁽³⁾	05/17/1999	04/28/2004	Common shares	628	47.58	D	
Option (right to buy) ⁽³⁾	05/17/1999	12/31/2004	Common shares	1,880	47.58	D	
Option (right to buy) ⁽³⁾	02/12/2000	02/11/2009	Common shares	3,667	45.22	D	
Option (right to buy) ⁽³⁾	02/12/2001	02/11/2009	Common shares	3,667	45.22	D	
Option (right to buy) ⁽³⁾	02/12/2002	02/11/2009	Common shares	3,666	45.22	D	
Option (right to buy) ⁽³⁾	02/11/2002	02/10/2010	Common shares	4,833	34.7	D	
Option (right to buy) ⁽³⁾	02/11/2003	02/10/2010	Common shares	4,833	34.7	D	
Option (right to buy) ⁽³⁾	02/09/2002	02/08/2011	Common shares	4,834	48.36	D	
Option (right to buy) ⁽³⁾	02/09/2003	02/08/2011	Common shares	4,833	48.36	D	
Option (right to buy) ⁽³⁾	02/09/2004	02/08/2011	Common shares	4,823	48.36	D	
Option (right to buy) ⁽³⁾	07/09/2002	07/08/2011	Common shares	5,000	47.47	D	
Option (right to buy) ⁽³⁾	07/09/2003	07/08/2011	Common shares	5,000	47.47	D	
Option (right to buy) ⁽³⁾	07/09/2004	07/08/2011	Common shares	5,000	47.47	D	
Option (right to buy) ⁽³⁾	06/22/2002	02/13/2007	Common shares	5,150	55.6	D	
Option (right to buy) ⁽³⁾	06/22/2002	04/27/2005	Common shares	3,073	55.6	D	
Option (right to buy) ⁽³⁾	06/22/2002	02/10/2010	Common shares	3,727	55.6	D	
Option (right to buy) ⁽³⁾	06/22/2002	02/12/2008	Common shares	6,289	55.6	D	
Option (right to buy) ⁽³⁾	02/15/2003	02/14/2012	Common shares	16,667	57.06	D	
Option (right to buy) ⁽³⁾	02/15/2004	02/14/2012	Common shares	16,666	57.06	D	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy) ⁽³⁾	02/15/2005	02/14/2012	Common shares	16,667	57.06	D	
Option (right to buy) ⁽³⁾	02/14/2004	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) ⁽³⁾	02/14/2005	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) ⁽³⁾	02/14/2006	02/13/2013	Common shares	20,000	35.36	D	
Option (right to buy) ⁽³⁾	11/30/2003	02/08/2006	Common shares	1,939	43.55	D	
Option (right to buy) ⁽³⁾	11/30/2003	02/13/2007	Common shares	2,650	43.55	D	
Option (right to buy) ⁽³⁾	02/20/2005	02/19/2014	Common shares	10,000	43.66	D	
Option (right to buy) ⁽³⁾	02/20/2006	02/19/2014	Common shares	10,000	43.66	D	
Option (right to buy) ⁽³⁾	02/20/2007	02/19/2014	Common shares	10,000	43.66	D	

Explanation of Responses:

- Balance in the Abbott Laboratories Stock Retirement Trust as of March 17, 2004.
- Reporting person disclaims beneficial ownership of shares held by his daughters.
- Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.

John A. Berry, Attorney-in-Fact for Holger A. Liepmann 03/22/2004

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned constitutes and appoints JOSE M. DE LASA, LAURA J. SCHUMACHER, JOHN A. BERRY and DEBORAH K. KOENEN, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, to sign any and all Securities and Exchange Commission ("SEC") statements of beneficial ownership of securities on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Dated: March 15, 2004

/s/ Holger A. Liepman

Signature of Reporting Person

Holger A. Liepman

Senior Vice President

Name and Title

Abbott Laboratories
100 Abbott Park
Abbott Park, IL 60064-6400
